BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 28049946)

  • 1. Ursodeoxycholic Acid Ameliorates Intrahepatic Cholestasis Independent of Biliary Bicarbonate Secretion in Vil2
    Hatano R; Kawaguchi K; Togashi F; Sugata M; Masuda S; Asano S
    Biol Pharm Bull; 2017; 40(1):34-42. PubMed ID: 28049946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Choleretic effects of ursodeoxycholic acid on experimentally-induced intrahepatic cholestasis.
    Mizoguchi Y; Miyajima K; Kioka K; Seki S; Kobayashi K; Morisawa S
    Osaka City Med J; 1989 Nov; 35(2):83-91. PubMed ID: 2628845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Knockdown of ezrin causes intrahepatic cholestasis by the dysregulation of bile fluidity in the bile duct epithelium in mice.
    Hatano R; Akiyama K; Tamura A; Hosogi S; Marunaka Y; Caplan MJ; Ueno Y; Tsukita S; Asano S
    Hepatology; 2015 May; 61(5):1660-71. PubMed ID: 25311759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytoprotection with ursodeoxycholic acid: effect in chronic non-cholestatic and chronic cholestatic liver disease.
    Lirussi F; Okolicsanyi L
    Ital J Gastroenterol; 1992 Jan; 24(1):31-5. PubMed ID: 1571577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells.
    He H; Mennone A; Boyer JL; Cai SY
    Hepatology; 2011 Feb; 53(2):548-57. PubMed ID: 21274875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corticotropin-releasing hormone expression in patients with intrahepatic cholestasis of pregnancy after ursodeoxycholic acid treatment: an initial experience.
    Zhou F; Zhang L; He MM; Liu ZF; Gao BX; Wang XD
    Curr Med Res Opin; 2014 Aug; 30(8):1529-35. PubMed ID: 24665980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of ursodeoxycholic acid in patients with liver disease.
    Angulo P
    Curr Gastroenterol Rep; 2002 Feb; 4(1):37-44. PubMed ID: 11825540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of cholestatic liver diseases].
    Gatzen M; Pausch J
    Med Klin (Munich); 2002 Mar; 97(3):152-9. PubMed ID: 11957790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis.
    Jacquemin E; Hermans D; Myara A; Habes D; Debray D; Hadchouel M; Sokal EM; Bernard O
    Hepatology; 1997 Mar; 25(3):519-23. PubMed ID: 9049190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ursodeoxycholic acid choleresis: relationship to biliary HCO-3 and effects of Na+-H+ exchange inhibitors.
    Renner EL; Lake JR; Cragoe EJ; Van Dyke RW; Scharschmidt BF
    Am J Physiol; 1988 Feb; 254(2 Pt 1):G232-41. PubMed ID: 2831731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited.
    Paumgartner G; Beuers U
    Hepatology; 2002 Sep; 36(3):525-31. PubMed ID: 12198643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease.
    Munoz-Garrido P; Marin JJ; Perugorria MJ; Urribarri AD; Erice O; Sáez E; Úriz M; Sarvide S; Portu A; Concepcion AR; Romero MR; Monte MJ; Santos-Laso Á; Hijona E; Jimenez-Agüero R; Marzioni M; Beuers U; Masyuk TV; LaRusso NF; Prieto J; Bujanda L; Drenth JP; Banales JM
    J Hepatol; 2015 Oct; 63(4):952-61. PubMed ID: 26044126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ursodeoxycholate inhibits mast cell activation and reverses biliary injury and fibrosis in Mdr2
    Meng F; Kennedy L; Hargrove L; Demieville J; Jones H; Madeka T; Karstens A; Chappell K; Alpini G; Sybenga A; Invernizzi P; Bernuzzi F; DeMorrow S; Francis H
    Lab Invest; 2018 Nov; 98(11):1465-1477. PubMed ID: 30143751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ursodeoxycholic acid treatment of vanishing bile duct syndromes.
    Pusl T; Beuers U
    World J Gastroenterol; 2006 Jun; 12(22):3487-95. PubMed ID: 16773706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacotherapy of cholestatic liver diseases.
    Paumgartner G
    J Dig Dis; 2010 Jun; 11(3):119-25. PubMed ID: 20579215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progesterone metabolites and bile acids in serum of patients with intrahepatic cholestasis of pregnancy: effect of ursodeoxycholic acid therapy.
    Meng LJ; Reyes H; Axelson M; Palma J; Hernandez I; Ribalta J; Sjövall J
    Hepatology; 1997 Dec; 26(6):1573-9. PubMed ID: 9398000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of ursodeoxycholic acid- and canrenoate-induced biliary bicarbonate secretion and the effect on glucose- and amino acid-induced cholestasis.
    Omland E; Mathisen O
    Scand J Gastroenterol; 1991 May; 26(5):513-22. PubMed ID: 1871544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis.
    Beuers U
    Nat Clin Pract Gastroenterol Hepatol; 2006 Jun; 3(6):318-28. PubMed ID: 16741551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating the effectiveness and safety of ursodeoxycholic acid in treatment of intrahepatic cholestasis of pregnancy: A meta-analysis (a prisma-compliant study).
    Kong X; Kong Y; Zhang F; Wang T; Yan J
    Medicine (Baltimore); 2016 Oct; 95(40):e4949. PubMed ID: 27749550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fetal cardiac dysfunction in intrahepatic cholestasis of pregnancy is associated with elevated serum bile acid concentrations.
    Vasavan T; Deepak S; Jayawardane IA; Lucchini M; Martin C; Geenes V; Yang J; Lövgren-Sandblom A; Seed PT; Chambers J; Stone S; Kurlak L; Dixon PH; Marschall HU; Gorelik J; Chappell L; Loughna P; Thornton J; Pipkin FB; Hayes-Gill B; Fifer WP; Williamson C
    J Hepatol; 2021 May; 74(5):1087-1096. PubMed ID: 33276032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.